Potential Vaccines and Post-Exposure Treatments for Filovirus Infections

Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.

• Publication year

  2012

• Venue

  Viruses

• Publication date

  2012-09-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3390/v4091619PMID 23170176PMCID 3499823
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Filoviridae: Marburg and ebola viruses

  2013cited by this paper
• A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

  2012cited by this paper
• Antibodies for prevention and treatment of respiratory syncytial virus infections in children.

  2012cited by this paper
• Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.

  2012cited by this paper
• Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever

  2012cited by this paper
• Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies

  2012cited by this paper
• Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease

  2012cited by this paper
• Recovery Potential of a Western Lowland Gorilla Population following a Major Ebola Outbreak: Results from a Ten Year Study

  2012cited by this paper
• Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates

  2012influential reference
• A Replicating Cytomegalovirus-Based Vaccine Encoding a Single Ebola Virus Nucleoprotein CTL Epitope Confers Protection against Ebola Virus

  2011cited by this paper
• Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus.

  2011cited by this paper
• Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes

  2011cited by this paper
• Hexamminecobalt (III) Chloride as a Broad-Spectrum Antiviral Complex

  2011cited by this paper
• Ebolavirus Δ-Peptide Immunoadhesins Inhibit Marburgvirus and Ebolavirus Cell Entry

  2011cited by this paper
• Filovirus vaccines.

  2011cited by this paper
• Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.

  2011influential reference
• Identification of a Small-Molecule Entry Inhibitor for Filoviruses

  2011cited by this paper
• Ebola virus entry requires the cholesterol transporter Niemann-Pick C1

  2011cited by this paper
• Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.

  2011cited by this paper
• Small molecule inhibitors reveal Niemann-Pick C1 is essential for ebolavirus infection

  2011cited by this paper
• High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection

  2011cited by this paper
• Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine

  2011cited by this paper
• Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

  2011cited by this paper
• Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

  2011cited by this paper
• T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus

  2011cited by this paper
• Antibody-dependent enhancement of Marburg virus infection.

  2011cited by this paper
• Correlates of Immunity to Filovirus Infection

  2011cited by this paper
• Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.

  2011cited by this paper
• Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.

  2011cited by this paper
• Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options.

  2011cited by this paper
• Addendum: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

  2011cited by this paper
• Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses

  2011cited by this paper
• Recent advances in Ebolavirus vaccine development

  2010influential reference
• Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations

  2010cited by this paper
• Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

  2010cited by this paper
• High‐level rapid production of full‐size monoclonal antibodies in plants by a single‐vector DNA replicon system

  2010cited by this paper
• Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection

  2010influential reference
• Alkylated Porphyrins Have Broad Antiviral Activity against Hepadnaviruses, Flaviviruses, Filoviruses, and Arenaviruses

  2010influential reference
• Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector

  2010cited by this paper
• Development of High-Content Imaging Assays for Lethal Viral Pathogens

  2010cited by this paper
• Advanced antisense therapies for postexposure protection against lethal filovirus infections

  2010cited by this paper
• A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

  2010influential reference
• A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

  2010cited by this paper
• A broad-spectrum antiviral targeting entry of enveloped viruses

  2010cited by this paper
• High-Content Assay to Identify Inhibitors of Dengue Virus Infection

  2010cited by this paper
• Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response

  2010cited by this paper
• Inhibition of heat-shock protein 90 reduces Ebola virus replication.

  2010cited by this paper
• Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

  2010cited by this paper
• Deficiency of Niemann-Pick Type C-1 Protein Impairs Release of Human Immunodeficiency Virus Type 1 and Results in Gag Accumulation in Late Endosomal/Lysosomal Compartments

  2009cited by this paper
• Newcastle Disease Virus-Vectored Vaccines Expressing the Hemagglutinin or Neuraminidase Protein of H5N1 Highly Pathogenic Avian Influenza Virus Protect against Virus Challenge in Monkeys

  2009cited by this paper
• Cholesterol Synthesis Inhibitor U18666A and the Role of Sterol Metabolism and Trafficking in Numerous Pathophysiological Processes

  2009cited by this paper
• Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge

  2009cited by this paper
• Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus

  2009cited by this paper
• Discovery of Swine as a Host for the Reston ebolavirus

  2009cited by this paper
• Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.

  2009influential reference
• Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen.

  2009cited by this paper
• Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine

  2009cited by this paper
• Drug targets in infections with Ebola and Marburg viruses.

  2009cited by this paper
• Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.

  2009cited by this paper
• Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection

  2009influential reference
• Identification of Upregulators of BMP2 Expression via High-Throughput Screening of a Synthetic and Natural Compound Library

  2009cited by this paper
• Development of a broad-spectrum antiviral with activity against Ebola virus.

  2009cited by this paper
• Lipidic Systems for In Vivo siRNA Delivery

  2009cited by this paper
• Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007

  2009cited by this paper
• Niemann-Pick C1 Functions Independently of Niemann-Pick C2 in the Initial Stage of Retrograde Transport of Membrane-impermeable Lysosomal Cargo*

  2009cited by this paper
• Heat-shock Protein 90 Is Essential for Stabilization of the Hepatitis C Virus Nonstructural Protein NS3*

  2009cited by this paper
• Protection against lethal challenge by Ebola virus-like particles produced in insect cells.

  2009cited by this paper
• Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus

  2009cited by this paper
• Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium

  2008cited by this paper
• Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections

  2008influential reference
• Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses

  2008cited by this paper
• Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates

  2008cited by this paper
• Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates

  2008cited by this paper
• Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies

  2008cited by this paper
• Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies.

  2008cited by this paper
• Marine Natural Product Libraries for High-Throughput Screening and Rapid Drug Discovery

  2008cited by this paper
• The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital.

  2007cited by this paper
• Heptad Repeat-Derived Peptides Block Protease-Mediated Direct Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus but Not Entry via the Endosomal Pathway

  2007cited by this paper
• Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys

  2007cited by this paper
• Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents.

  2007cited by this paper
• Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2

  2007cited by this paper
• Dengue and dengue hemorrhagic fever: management issues in an intensive care unit.

  2007cited by this paper
• Drugs for bad bugs: confronting the challenges of antibacterial discovery

  2007cited by this paper
• Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

  2007influential reference
• Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species.

  2007cited by this paper
• Immunogenicity of the outer domain of a HIV-1 clade C gp120

  2007cited by this paper
• Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

  2007cited by this paper
• Cell penetrating peptide conjugates of steric block oligonucleotides

  2007cited by this paper
• Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.

  2007cited by this paper
• The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. lessons learned in the community.

  2007cited by this paper
• TAT transduction: the molecular mechanism and therapeutic prospects.

  2007cited by this paper
• Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

  2007cited by this paper
• Effective Post-Exposure Treatment of Ebola

  2007cited by this paper
• Epitopes required for antibody-dependent enhancement of Ebola virus infection.

  2007cited by this paper
• Protective efficacy of neutralizing antibodies against Ebola virus infection.

  2007cited by this paper
• Ebolavirus and Other Filoviruses

  2007cited by this paper
• Effective Post-Exposure Treatment of Ebola Infection

  2007cited by this paper
• Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus

  2007cited by this paper
• Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

  2007cited by this paper
• Dengue e dengue hemorrágico: aspectos do manejo na unidade de terapia intensiva

  2007cited by this paper

• Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification

  2025cites this paper
• Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification

  2025cites this paper
• Ebola et la maladie à filovirus : enjeux et perspectives à l’horizon 2030

  2023cites this paper
• A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health

  2022cites this paper
• Ebolavirus and Marburgvirus Infections

  2022cites this paper
• Ebola and Marburg Virus: A Brief Review

  2020cites this paper
• The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms

  2020cites this paper
• UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments

  2019cites this paper
• Edinburgh Research Explorer UK vaccines network

  2019cites this paper
• Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates

  2019cites this paper
• A novel electrochemical DNA biosensor for Ebola virus detection.

  2018cites this paper
• Epidemiology and Immunopathogenesis of Ebola and Flaviviruses

  2018cites this paper
• Filovirus – Auslöser von hämorrhagischem Fieber

  2018cites this paper
• Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins

  2018cites this paper
• Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice

  2017cites this paper
• Kinase Inhibitors and Nucleoside Analogues as Novel Therapies to Inhibit HIV-1 or ZEBOV Replication

  2017cites this paper
• Will There Be a Cure for Ebola?

  2017cites this paper
• Ebola Virus Makona Shows Reduced Lethality in an Immune-deficient Mouse Model.

  2016cites this paper
• Antiviral therapeutics for the treatment of Ebola virus infection.

  2016cites this paper
• Ebola virus disease and critical illness

  2016cites this paper
• Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic

  2016cites this paper
• Recent advances in the development of vaccines for Ebola virus disease.

  2016cites this paper
• Molecular mechanisms of Ebola pathogenesis

  2016cites this paper
• In-silico epitope based vaccine an excellent solution against Marburg virus

  2016cites this paper
• Immune Evasion in Ebolavirus Infections

  2015cites this paper
• Development of Small‐Molecule Antivirals for Ebola

  2015cites this paper
• Ebola and Marburg haemorrhagic fever.

  2015cites this paper
• [Illness due the Ebola virus: epidemiology and clinical manifestations within the context of an international public health emergency].

  2015cites this paper
• Situación actual de las vacunas frente al virus del Ébola

  2015cites this paper
• Ebola Virus Disease

  2015cites this paper
• VSVΔG/EBOV GP-Induced Innate Protection Enhances Natural Killer Cell Activity to Increase Survival in a Lethal Mouse Adapted Ebola Virus Infection

  2015cites this paper
• An Adaptive Neuro-Fuzzy Inference System for Diagnosis of EHF .

  2015cites this paper
• Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment

  2015cites this paper
• AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.

  2015cites this paper
• Transmission of ebola virus disease: an overview.

  2015cites this paper
• Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit.

  2015cites this paper
• Three minimal sequences found in Ebola virus genomes and absent from human DNA

  2015cites this paper
• Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

  2015cites this paper
• A Review on Transmission of Ebola Virus Disease

  2015cites this paper
• La biotecnología en la salud humana: el hito de los anticuerpos monoclonales

  2014cites this paper
• Ebolavirus and Marburgvirus Infections

  2014cites this paper
• Ebolavirus in West Africa, and the use of experimental therapies or vaccines

  2014cites this paper
• What clinicians should know about the 2014 Ebola outbreak.

  2014cites this paper
• Filoviruses: Marburg and ebola

  2014cites this paper
• The Ebola virus: a review of progress and development in research

  2014cites this paper
• Ebola virus and other Filoviruses: an overview

  2014cites this paper
• Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.

  2014cites this paper
• Pharmacotherapy of Ebola hemorrhagic fever: a brief review of current status and future perspectives.

  2014cites this paper
• Ebola--a growing threat?

  2014cites this paper
• The little things.

  2014cites this paper
• A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein

  2013cites this paper
• Animal models for Ebola and Marburg virus infections

  2013cites this paper
• Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

  2013cites this paper
• Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1

  2013cites this paper
• Arenaviruses and Filoviruses

  2011cites this paper